Evidence map›Paper›PMID 33361604›Full record

ArticleJournal of Alzheimer's disease : JAD2021

Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations.

Pratishtha Chatterjee, Anne M Fagan, Chengjie Xiong, Matthew McKay, Atul Bhatnagar, Yunqi Wu, Abhay K Singh, Kevin Taddei, Ian Martins, Samantha L Gardener and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Fluid biomarkers in cerebral amyloid angiopathy.Frontiers in neuroscience · 2024
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 4 countries.

Pratishtha ChatterjeeDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.
Anne M FaganDepartment of Neurology, Washington University, St. Louis, MO, USA.
Chengjie XiongKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA.
Matthew McKayAustralian Proteome Analysis Facility, Macquarie University, North Ryde, NSW, Australia.
Atul BhatnagarAustralian Proteome Analysis Facility, Macquarie University, North Ryde, NSW, Australia.
Yunqi WuAustralian Proteome Analysis Facility, Macquarie University, North Ryde, NSW, Australia.
Abhay K SinghMacquarie Business School, Macquarie University, North Ryde, NSW, Australia.
Kevin TaddeiSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Ian MartinsSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Samantha L GardenerSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Mark P MolloyAustralian Proteome Analysis Facility, Macquarie University, North Ryde, NSW, Australia.
Gerhard MulthaupDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Colin L MastersThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VA, Australia.
Peter R SchofieldNeuroscience Research Australia, Sydney, NSW, Australia.
Tammie L S BenzingerKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA.
John C MorrisDepartment of Neurology, Washington University, St. Louis, MO, USA.
Randall J BatemanDepartment of Neurology, Washington University, St. Louis, MO, USA.
Steven M GreenbergDepartment of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts, USA.
Marieke J H WermerDepartment of Radiology, Leiden University Medical Center, Leiden, Netherlands.
Mark A van BuchemDepartment of Radiology, Leiden University Medical Center, Leiden, Netherlands.
Hamid R SohrabiDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.
Ralph N MartinsDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia.
Dominantly Inherited Alzheimer Network
Edith Cowan University · AUWashington University in St. Louis · USAGRF Ltd · AUHarvard University · USThe University of Melbourne · AULeiden University Medical Center · NLThe University of Sydney · AU

Funding

Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
NIA NIH HHS U19 AG032438
6 · The paper itself

Abstract

backgroundCerebral amyloid angiopathy (CAA) is one of the major causes of intracerebral hemorrhage and vascular dementia in older adults. Early diagnosis will provide clinicians with an opportunity to intervene early with suitable strategies, highlighting the importance of pre-symptomatic CAA biomarkers.

objectiveInvestigation of pre-symptomatic CAA related blood metabolite alterations in Dutch-type hereditary CAA mutation carriers (D-CAA MCs).

methodsPlasma metabolites were measured using mass-spectrometry (AbsoluteIDQ® p400 HR kit) and were compared between pre-symptomatic D-CAA MCs (n = 9) and non-carriers (D-CAA NCs, n = 8) from the same pedigree. Metabolites that survived correction for multiple comparisons were further compared between D-CAA MCs and additional control groups (cognitively unimpaired adults).

results275 metabolites were measured in the plasma, 22 of which were observed to be significantly lower in theD-CAAMCs compared to D-CAA NCs, following adjustment for potential confounding factors age, sex, and APOE ε4 (p < 00.05). After adjusting for multiple comparisons, only spermidine remained significantly lower in theD-CAAMCscompared to theD-CAA NCs (p  < 0.00018). Plasma spermidine was also significantly lower in D-CAA MCs compared to the cognitively unimpaired young adult and older adult groups (p < 0.01). Spermidinewas also observed to correlate with CSF Aβ40 (rs = 0.621, p = 0.024), CSF Aβ42 (rs = 0.714, p = 0.006), and brain Aβ load (rs = -0.527, p = 0.030).

conclusionThe current study provides pilot data on D-CAA linked metabolite signals, that also associated with Aβ neuropathology and are involved in several biological pathways that have previously been linked to neurodegeneration and dementia.

Indexed as

AdultAsymptomatic DiseasesBiomarkersCase-Control StudiesCerebral Amyloid Angiopathy, FamilialFemaleHeterozygoteHumansMaleMass SpectrometryMental Status and Dementia TestsMetabolomicsNeuroimagingPedigreePlaque, AmyloidPositron-Emission TomographyBiomarkersSpermidineBlood biomarkerscerebral amyloid angiopathyearly diagnosishereditary cerebral hemorrhage with amyloidosis - dutch typeintracerebral hemorrhagemetabolomicsvascular dementia

Identifiers

PMID33361604
PMCPMC8057860
OpenAlexW3099031833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.